APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD133 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD133 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchCD133 Antibody Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal CD133 Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CD133 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD133 Antibody Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal CD133 Antibody Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global CD133 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD133 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD133 Antibody market include Thermo Fisher Scientific, Boster Biological Technology, United States Biological, Proteintech, NSJ Bioreagents, Miltenyi Biotec, HUABIO, GeneTex and Cell Signaling Technology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD133 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD133 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD133 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD133 Antibody market.

CD133 Antibody Segment by Company

Thermo Fisher Scientific

Boster Biological Technology

United States Biological

Proteintech

NSJ Bioreagents

Miltenyi Biotec

HUABIO

GeneTex

Cell Signaling Technology

Bioss

BioLegend

Beckman Coulter

Abcam

CD133 Antibody Segment by Type

Polyclonal

Monoclonal

CD133 Antibody Segment by Application

Western Blot

Enzyme Linked Immunosorbent Assay

Immunocytochemistry

Immunohistochemistry

Others

CD133 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CD133 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD133 Antibody key companies, revenue, market share, and recent developments.

3. To split the CD133 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD133 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD133 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CD133 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD133 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD133 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD133 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD133 Antibody industry.

Chapter 3: Detailed analysis of CD133 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD133 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD133 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD133 Antibody Industry Trends Table 2. CD133 Antibody Industry Drivers Table 3. CD133 Antibody Industry Opportunities and Challenges Table 4. CD133 Antibody Industry Restraints Table 5. Global CD133 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD133 Antibody Revenue Share by Company (2021-2026) Table 7. Global CD133 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD133 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global CD133 Antibody Company, Product Type & Application Table 10. Global CD133 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD133 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global CD133 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CD133 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CD133 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CD133 Antibody Sales Value Share by Type (2021-2026) Table 20. Global CD133 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Enzyme Linked Immunosorbent Assay Table 23. Significant Companies of Immunocytochemistry Table 24. Significant Companies of Immunohistochemistry Table 25. Significant Companies of Others Table 26. Global CD133 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CD133 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global CD133 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global CD133 Antibody Sales Value Share by Application (2021-2026) Table 30. Global CD133 Antibody Sales Value Share by Application (2027-2032) Table 31. Global CD133 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CD133 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global CD133 Antibody Sales Value Share by Region (2021-2026) Table 34. Global CD133 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global CD133 Antibody Sales Value Share by Region (2027-2032) Table 36. Global CD133 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global CD133 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global CD133 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global CD133 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global CD133 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific CD133 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Boster Biological Technology Company Information Table 47. Boster Biological Technology Business Overview Table 48. Boster Biological Technology CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Boster Biological Technology CD133 Antibody Product Portfolio Table 50. Boster Biological Technology Recent Development Table 51. United States Biological Company Information Table 52. United States Biological Business Overview Table 53. United States Biological CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. United States Biological CD133 Antibody Product Portfolio Table 55. United States Biological Recent Development Table 56. Proteintech Company Information Table 57. Proteintech Business Overview Table 58. Proteintech CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Proteintech CD133 Antibody Product Portfolio Table 60. Proteintech Recent Development Table 61. NSJ Bioreagents Company Information Table 62. NSJ Bioreagents Business Overview Table 63. NSJ Bioreagents CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. NSJ Bioreagents CD133 Antibody Product Portfolio Table 65. NSJ Bioreagents Recent Development Table 66. Miltenyi Biotec Company Information Table 67. Miltenyi Biotec Business Overview Table 68. Miltenyi Biotec CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Miltenyi Biotec CD133 Antibody Product Portfolio Table 70. Miltenyi Biotec Recent Development Table 71. HUABIO Company Information Table 72. HUABIO Business Overview Table 73. HUABIO CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. HUABIO CD133 Antibody Product Portfolio Table 75. HUABIO Recent Development Table 76. GeneTex Company Information Table 77. GeneTex Business Overview Table 78. GeneTex CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. GeneTex CD133 Antibody Product Portfolio Table 80. GeneTex Recent Development Table 81. Cell Signaling Technology Company Information Table 82. Cell Signaling Technology Business Overview Table 83. Cell Signaling Technology CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Cell Signaling Technology CD133 Antibody Product Portfolio Table 85. Cell Signaling Technology Recent Development Table 86. Bioss Company Information Table 87. Bioss Business Overview Table 88. Bioss CD133 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bioss CD133 Antibody Product Portfolio Table 90. Bioss Recent Development Table 91. BioLegend Company Information Table 92. BioLegend Business Overview Table 93. BioLegend CD133 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. BioLegend CD133 Antibody Product Portfolio Table 95. BioLegend Recent Development Table 96. Beckman Coulter Company Information Table 97. Beckman Coulter Business Overview Table 98. Beckman Coulter CD133 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Beckman Coulter CD133 Antibody Product Portfolio Table 100. Beckman Coulter Recent Development Table 101. Abcam Company Information Table 102. Abcam Business Overview Table 103. Abcam CD133 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Abcam CD133 Antibody Product Portfolio Table 105. Abcam Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. CD133 Antibody Product Image Figure 2. Global CD133 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD133 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global CD133 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global CD133 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CD133 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CD133 Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Enzyme Linked Immunosorbent Assay Image Figure 14. Immunocytochemistry Image Figure 15. Immunohistochemistry Image Figure 16. Others Image Figure 17. Global CD133 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CD133 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global CD133 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global CD133 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global CD133 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America CD133 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America CD133 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe CD133 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe CD133 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific CD133 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific CD133 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America CD133 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America CD133 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa CD133 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa CD133 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt CD133 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt CD133 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt CD133 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Enzyme Linked Immunosorbent Assay
  • Immunocytochemistry
  • Immunohistochemistry
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Boster Biological Technology
  • United States Biological
  • Proteintech
  • NSJ Bioreagents
  • Miltenyi Biotec
  • HUABIO
  • GeneTex
  • Cell Signaling Technology
  • Bioss
  • BioLegend
  • Beckman Coulter
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD133 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD133 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD133 Antibody Market Dynamics
  1. 2.1 CD133 Antibody Industry Trends
  2. 2.2 CD133 Antibody Industry Drivers
  3. 2.3 CD133 Antibody Industry Opportunities and Challenges
  4. 2.4 CD133 Antibody Industry Restraints
3 CD133 Antibody Market by Company
  1. 3.1 Global CD133 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CD133 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CD133 Antibody Company Ranking (2024-2026)
  4. 3.4 Global CD133 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global CD133 Antibody Company Product Type and Application
  6. 3.6 Global CD133 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD133 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD133 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD133 Antibody Market by Type
  1. 4.1 CD133 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global CD133 Antibody Sales Value by Type
  5. 4.2.1 Global CD133 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CD133 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global CD133 Antibody Sales Value Share by Type (2021-2032)
5 CD133 Antibody Market by Application
  1. 5.1 CD133 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Enzyme Linked Immunosorbent Assay
  4. 5.1.3 Immunocytochemistry
  5. 5.1.4 Immunohistochemistry
  6. 5.1.5 Others
  7. 5.2 Global CD133 Antibody Sales Value by Application
  8. 5.2.1 Global CD133 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CD133 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global CD133 Antibody Sales Value Share by Application (2021-2032)
6 CD133 Antibody Regional Value Analysis
  1. 6.1 Global CD133 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD133 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD133 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD133 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD133 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America CD133 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD133 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe CD133 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD133 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD133 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD133 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America CD133 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD133 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD133 Antibody Sales Value Share by Country, 2025 VS 2032
7 CD133 Antibody Country-level Value Analysis
  1. 7.1 Global CD133 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD133 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD133 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD133 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD133 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD133 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD133 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD133 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD133 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD133 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD133 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD133 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD133 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD133 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD133 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD133 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD133 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD133 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD133 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD133 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD133 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD133 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD133 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD133 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD133 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD133 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD133 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD133 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD133 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD133 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD133 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD133 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD133 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD133 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD133 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific CD133 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific CD133 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology CD133 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology CD133 Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological CD133 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological CD133 Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Proteintech
  20. 8.4.1 Proteintech Company Information
  21. 8.4.2 Proteintech Business Overview
  22. 8.4.3 Proteintech CD133 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Proteintech CD133 Antibody Product Portfolio
  24. 8.4.5 Proteintech Recent Developments
  25. 8.5 NSJ Bioreagents
  26. 8.5.1 NSJ Bioreagents Company Information
  27. 8.5.2 NSJ Bioreagents Business Overview
  28. 8.5.3 NSJ Bioreagents CD133 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NSJ Bioreagents CD133 Antibody Product Portfolio
  30. 8.5.5 NSJ Bioreagents Recent Developments
  31. 8.6 Miltenyi Biotec
  32. 8.6.1 Miltenyi Biotec Company Information
  33. 8.6.2 Miltenyi Biotec Business Overview
  34. 8.6.3 Miltenyi Biotec CD133 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Miltenyi Biotec CD133 Antibody Product Portfolio
  36. 8.6.5 Miltenyi Biotec Recent Developments
  37. 8.7 HUABIO
  38. 8.7.1 HUABIO Company Information
  39. 8.7.2 HUABIO Business Overview
  40. 8.7.3 HUABIO CD133 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 HUABIO CD133 Antibody Product Portfolio
  42. 8.7.5 HUABIO Recent Developments
  43. 8.8 GeneTex
  44. 8.8.1 GeneTex Company Information
  45. 8.8.2 GeneTex Business Overview
  46. 8.8.3 GeneTex CD133 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GeneTex CD133 Antibody Product Portfolio
  48. 8.8.5 GeneTex Recent Developments
  49. 8.9 Cell Signaling Technology
  50. 8.9.1 Cell Signaling Technology Company Information
  51. 8.9.2 Cell Signaling Technology Business Overview
  52. 8.9.3 Cell Signaling Technology CD133 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cell Signaling Technology CD133 Antibody Product Portfolio
  54. 8.9.5 Cell Signaling Technology Recent Developments
  55. 8.10 Bioss
  56. 8.10.1 Bioss Company Information
  57. 8.10.2 Bioss Business Overview
  58. 8.10.3 Bioss CD133 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bioss CD133 Antibody Product Portfolio
  60. 8.10.5 Bioss Recent Developments
  61. 8.11 BioLegend
  62. 8.11.1 BioLegend Company Information
  63. 8.11.2 BioLegend Business Overview
  64. 8.11.3 BioLegend CD133 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioLegend CD133 Antibody Product Portfolio
  66. 8.11.5 BioLegend Recent Developments
  67. 8.12 Beckman Coulter
  68. 8.12.1 Beckman Coulter Company Information
  69. 8.12.2 Beckman Coulter Business Overview
  70. 8.12.3 Beckman Coulter CD133 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beckman Coulter CD133 Antibody Product Portfolio
  72. 8.12.5 Beckman Coulter Recent Developments
  73. 8.13 Abcam
  74. 8.13.1 Abcam Company Information
  75. 8.13.2 Abcam Business Overview
  76. 8.13.3 Abcam CD133 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abcam CD133 Antibody Product Portfolio
  78. 8.13.5 Abcam Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst